Navigation Links
Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders
Date:9/8/2008

onder patients chronically infected with HCV genotype 2 or 3. The primary objective was to assess the safety, tolerability, pharmacokinetics and antiviral activity of R7128 in the clinically-relevant setting of combination therapy for chronic HCV infection. Cohort 1 administered R7128 500mg BID, Cohort 2 administered R7128 1500mg BID, and Cohort 3 administered an intermediate dose of 1000mg BID, all given in combination with pegylated interferon and ribavirin for 28 days. All subjects then went on to receive a total of 48 weeks of the standard-of-care regimen. In Cohort 4, patients with HCV genotype 2 or 3 who did not achieve an SVR with previous interferon-based therapy were administered R7128 1500mg BID in combination with SOC for 4 weeks, and subsequently treated with an additional 20 weeks of SOC.

About R7128

R7128 is being developed for the treatment of chronic HCV infection. R7128 is a prodrug of PSI-6130, a cytidine nucleoside analog inhibitor of HCV RNA polymerase. A prodrug is a chemically modified form of a molecule designed to enhance the absorption, distribution and metabolic properties of that molecule. R7128 has shown in vitro activity against all of the most common HCV genotypes (1, 2, 3 and 4).

Results from an oral single ascending dose study of PSI-6130 in 24 healthy male volunteers showed that PSI-6130 was generally well tolerated with no serious adverse events in doses up to 3000 mg.

R7128 demonstrated significant, dose-dependent antiviral activity across four prior treatment-failure patient cohorts (n=40) receiving 750 mg or 1500 mg administered either once-daily or twice-daily for 14 days as monotherapy. The greatest mean decrease in HCV RNA from baseline was demonstrated in the patient cohort that received 1500 mg twice-daily, the highest dose of R7128 administered in the study. These patients demonstrated a mean 2.7 log10 IU/mL (>99%) decrease in HCV RNA. There was no evidence of the development of viral resistance
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Pharmasset to Present at the Upcoming Citibank and Morgan Stanley Investor Conferences
2. Pharmasset to Present at the Canaccord Adams Global Growth Conference on Tuesday, August 12th
3. Pharmasset Announces $25.9 Million Registered Direct Offering of Common Stock
4. Pharmasset Joins Russell 3000 Index
5. Pharmasset to Present at the Needham & Co. Biotechnology and Medical Technology Conference on Wednesday, June 11th
6. Pharmasset Selected to Join the NASDAQ Biotechnology Index
7. Pharmasset to Present at the Morgan Stanley Global Healthcare Conference on Wednesday, April 30th
8. Pharmasset Adds Two Cohorts to R7128 Hepatitis C Study
9. Pharmasset to Present at the Canaccord Adams Hepatitis C Conference on Wednesday, April 9th
10. Pharmasset Receives $10 Million of Working Capital
11. Pharmasset Appoints Herbert J. Conrad as a Director
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... ... July 27, 2015 , ... Production of high tenacity filament yarn ... years in the EU. For instance, it surpassed the EUR 106 million mark (in ... in 2010. Germany is a major producer, while Italy is a key consumer. ...
(Date:7/27/2015)... According to the new Market Research ... Media), by Application (Biobanking, Regenerative Medicine, Drug Discovery), by Geography ... , Asia-Pacific , Rest of the World) ... market was valued at $247.7 million in 2014, which is ... a CAGR of 18.2% between 2014 and 2019. ...
(Date:7/26/2015)... ... July 26, 2015 , ... ... VALIDATE® ANEMIA calibration verification / linearity test kit. The VALIDATE® ANEMIA kit contains ... ANEMIA kit is prepared using the CLSI recommended “equal delta” method for linearity ...
(Date:7/24/2015)... , July 24, 2015  Champions Oncology (OTC-BB: ... technology solutions and services to personalize the development and ... its financial and operational results for the fourth quarter ... Tuesday, July 28, 2015, before market open. ... the results that day at 9:00 a.m. EDT (6:00 ...
Breaking Biology Technology:High Tenacity Filament Yarn of Viscose Rayon Consumption to Grow Swiftly in the EU, Forecasts BAC Reports in New Study Available at MarketPublishers.com 2Global Biopreservation Media Market to be Worth $571.5 Million by 2019 2Global Biopreservation Media Market to be Worth $571.5 Million by 2019 3Maine Standards Company, LLC Announces Release of VALIDATE® ANEMIA Calibration Verification / Linearity Test Kit 2Champions Oncology to Announce Fourth Quarter Financial Results on Tuesday, July 28 2
... LLC (, http://www.CJPS-Enterprises.com ) announced that it ... services to leverage companies, intellectual property (IP) to ... of their intangible assets.,This customized service is execution-driven, ... a firm that specializes in growing,companies in the ...
... ... Prostate Surgery, SAN DIEGO, Nov. ... InnerCool Therapies, Inc., today,announced that it has developed a pelvic cooling ... surgery,for prostate cancer (radical prostatectomy). The new technology is being,applied in ...
... Vitamin E May Help,Prevent, Cardiovascular Events in Hp2-2 ... (Amex: SYI ) today announced new data demonstrating ... Diabetes may result,in an increased risk of heart attack ... today at the Annual Scientific,Sessions of the American Heart ...
Cached Biology Technology:CJPS Enterprises Provides New Strategies To Create Additional Revenues for Companies with Intellectual Property 2Cardium's InnerCool Announces New Tissue-Specific UroCool(TM) System for Use in Prostate Surgeries 2Cardium's InnerCool Announces New Tissue-Specific UroCool(TM) System for Use in Prostate Surgeries 3Cardium's InnerCool Announces New Tissue-Specific UroCool(TM) System for Use in Prostate Surgeries 4Cardium's InnerCool Announces New Tissue-Specific UroCool(TM) System for Use in Prostate Surgeries 5Cardium's InnerCool Announces New Tissue-Specific UroCool(TM) System for Use in Prostate Surgeries 6Cardium's InnerCool Announces New Tissue-Specific UroCool(TM) System for Use in Prostate Surgeries 7Cardium's InnerCool Announces New Tissue-Specific UroCool(TM) System for Use in Prostate Surgeries 8Synvista Therapeutics Announces Data Further Demonstrating the Value of Haptoglobin Genotyping in Diabetic Patients During AHA Meeting 2Synvista Therapeutics Announces Data Further Demonstrating the Value of Haptoglobin Genotyping in Diabetic Patients During AHA Meeting 3Synvista Therapeutics Announces Data Further Demonstrating the Value of Haptoglobin Genotyping in Diabetic Patients During AHA Meeting 4
(Date:7/2/2015)... DUBLIN , June 25, 2015 ... the addition of the "Next Generation Biometrics Market ... to 2020" report to their offering. ... $24.4 Billion by 2020, at a CAGR of 17.9% ... is the leading application for the market. Safran ...
(Date:6/30/2015)... 30, 2015 Genisphere announced ... to help further develop Genisphere,s therapeutics capabilities and portfolio. ... having spent much of the last 25 years in ... Bioscience, and Johnson & Johnson. Tom started his career ... Biotech Corporate Finance. He graduated from Dartmouth College with ...
(Date:6/25/2015)... DALLAS , June 25, 2015 ... report "Fingerprint Sensors Market by Type (Swipe & Area), Technology, ... (Mobile, Government, Healthcare, Commercial Security & Others) & ... published by marketsandmarkets, the said market is expected ... CAGR of 17.1%. Browse 76 ...
Breaking Biology News(10 mins):Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4
... Mount Sinai School of Medicine have found in a ... Mount Sinai stabilized or improved cardiac function in people ... of the therapy, called SERCA2a, experienced substantial clinical benefit ... need in this population. The data are published online ...
... Some areas of the southern United States are suffering from ... University study shows that could prove problematic for aquatic organisms. ... some chemicals in the environment more toxic to fish and ... exacerbate the magnitudes of the natural pH shifts in the ...
... seawater algae could hold the key to crops as a ... climates. Researchers at the University of Edinburgh have found ... its main food source is in short supply. Understanding ... when nutrients are scarce and to grow high-yield plants for ...
Cached Biology News:Mount Sinai researchers develop new gene therapy for heart failure 2Study shows climate change makes some chemicals more toxic to aquatic life 2
... system, 100-120 V, is used for biolistic ... handheld device employs an adjustable helium pulse ... gold microcarriers from the inner wall of ... cells. This system has a 2 square-centimeter ...
... Clean and Accurate Results Laser Capture ... the sensitivity and accuracy of molecular assays ... types and multi-cellular structures isolated from whole ... to microdissection-developed in 1996 at the National ...
...
Mouse monoclonal antibody raised against a partial recombinant DHX8. NCBI Entrez Gene ID = DHX8...
Biology Products: